DiaMedica Therapeutics Enrolls 200th Patient in Phase 2/3 Stroke Trial
DiaMedica Therapeutics said the 200th patient has enrolled in its REMEDY2 Phase 2/3 acute ischemic stroke trial.
DiaMedica Therapeutics said the 200th patient has enrolled in its REMEDY2 Phase 2/3 acute ischemic stroke trial.